Development Stage: Translational Biomarker Discovery
Regulatory Context: Pre-IND / EMA Scientific Advice–Compatible
Study Type: Phase 0 / Early Phase I Exploratory Biomarker Trial
Design Category: Mechanistic Signal Detection Study
SECTION 1 — STUDY OBJECTIVES
1.1 Primary Objective
To evaluate the effect of EMN-PM1 on predefined multi-scale resilience biomarkers:
- NAD+/NADH ratio
- Plasma MMP-9
- Heart Rate Variability (HRV) coherence
- Cortisol pulse variability
1.2 Secondary Objectives
- Evaluate dose-dependent mitochondrial enrichment
- Assess ECM turnover normalization markers
- Quantify neuroendocrine rhythm stabilization
- Assess safety and tolerability
1.3 Exploratory Objectives
- Evaluate collagen degradation fragments
- Assess SIRT1 activity
- Measure inflammatory cytokine modulation
- Characterize PK/PD relationship
SECTION 2 — STUDY DESIGN
2.1 Study Type
Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study
2.2 Population
Target Population:
- Adults aged 35–60
- Evidence of elevated metabolic stress markers
- Subclinical elevated cortisol variability
- Mild HRV dysregulation
Exclusion Criteria:
- Active autoimmune disease
- Major psychiatric disorder
- Uncontrolled cardiovascular disease
- Mineral metabolism disorders
- Current strong AMPK activator therapy
2.3 Sample Size
Total Participants: 80
Cohort Structure:
Cohort 1: Placebo (n=20)
Cohort 2: Low Dose (n=20)
Cohort 3: Mid Dose (n=20)
Cohort 4: High Dose (n=20)
Power:
80% power to detect ≥20% biomarker change at α=0.05
SECTION 3 — DOSING REGIMEN
Route: Oral
Duration: 28 Days
Dosing Frequency:
Once daily, morning administration
Dose Escalation:
Sequential cohort escalation after DSMB safety review
SECTION 4 — BIOMARKER PANEL
4.1 Primary Biomarkers
A. Mitochondrial Axis
- NAD+/NADH ratio (LC-MS)
- ATP/AMP ratio
- Mitochondrial DNA copy number
B. ECM Axis
- Plasma MMP-9
- Collagen degradation fragments (CTX)
- TIMP-1 levels
C. Neuroendocrine Axis
- Salivary cortisol diurnal curve
- 24-hour cortisol variability index
- HRV coherence score
4.2 Secondary Biomarkers
- SIRT1 activity assay
- IL-6, TNF-alpha
- CRP
- BDNF levels
4.3 Safety Biomarkers
- ALT / AST
- Creatinine
- Zinc / Copper serum levels
- ECG monitoring
SECTION 5 — ASSESSMENT SCHEDULE
Day -14 to 0: Screening & Baseline
- Full biomarker panel
- HRV baseline
- Cortisol diurnal mapping
- Safety labs
Day 7: Interim PK + Biomarker Snapshot
Day 14: Midpoint Biomarker Assessment
Day 28: Full Biomarker Panel
Day 42: Post-treatment Washout Assessment
SECTION 6 — ENDPOINTS
6.1 Primary Endpoint
Change from baseline to Day 28 in:
- NAD+/NADH ratio
- Plasma MMP-9
- HRV coherence
- Cortisol variability index
6.2 Secondary Endpoints
- Dose-response slope
- Correlation between mitochondrial enrichment and biomarker shift
- Change in collagen turnover markers
6.3 Safety Endpoints
- Incidence of adverse events
- QT interval change
- Hormonal suppression beyond physiological range
SECTION 7 — STATISTICAL ANALYSIS PLAN
Analysis Population:
- Intent-to-Treat (ITT)
- Per-Protocol
Statistical Tests:
- Mixed-effects repeated measures model
- ANCOVA with baseline adjustment
- Dose-response modeling
- Pearson/Spearman biomarker correlation
Multiplicity Adjustment:
False discovery rate (FDR) control for exploratory biomarkers
Success Criteria:
At least 2 of 4 primary biomarkers show statistically significant improvement vs placebo.
SECTION 8 — PK/PD MODELING
PK Sampling:
- 0h, 1h, 3h, 6h, 12h post-dose (Day 1 & Day 28)
Modeling:
- Non-compartmental analysis
- Exposure-response modeling
- Biomarker correlation modeling
Objective:
Define therapeutic window and biomarker-linked dose optimization.
SECTION 9 — RISK MITIGATION
Monitoring:
- Weekly safety labs
- DSMB oversight
- Mineral level monitoring
- Cortisol flattening threshold
Stopping Criteria:
- ≥3x ALT elevation
- Persistent cortisol suppression
- QT prolongation >20 ms
- Severe adverse event
SECTION 10 — GO / NO-GO DECISION FRAMEWORK
Advance to Phase I Expansion if:
- ≥20% improvement in NAD+/NADH
- ≥20% reduction in MMP-9
- Improved HRV coherence
- Acceptable safety profile
Reformulate or Adjust Dose if:
- Mineral imbalance
- Excessive AMPK activation signature
- Cortisol over-suppression
Terminate if:
- Significant cardiac signal
- Organ toxicity
- No biomarker signal
SECTION 11 — REGULATORY POSITIONING
Trial Classification:
Mechanistic Biomarker Discovery Study
Regulatory Strategy:
- Supports Pre-IND consultation
- Supports EMA Scientific Advice
- Provides Module 2.7 clinical summary basis
SECTION 12 — PROJECTED TIMELINE
Protocol Development: 3 months
Site Initiation: 3 months
Enrollment: 6 months
Study Duration: 2 months per participant
Data Analysis: 3 months
Total Estimated Timeline: 12–15 months
BIOMARKER DISCOVERY BLUEPRINT — COMPLETE
If desired:
A. Generate Full Phase I First-in-Human Protocol
B. Generate DSMB Charter
C. Generate Investigator Brochure
D. Generate Adaptive Trial Version (Seamless Phase I/IIa)
E. Generate Statistical Analysis Plan (SAP) Full Version
Respond with the letter only.